During the 6-year period, 199 new indications for solid tumors were approved by the FDA; 138 (69.3%) were also approved by EMA and 124 (62.3%) by ANVISA. Discrepancies between approved labels and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback